» Articles » PMID: 33042743

Choice of Nanovaccine Delivery Mode Has Profound Impacts on the Intralymph Node Spatiotemporal Distribution and Immunotherapy Efficacy

Overview
Journal Adv Sci (Weinh)
Date 2020 Oct 12
PMID 33042743
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Nanovaccines have attracted booming interests in vaccinology studies, but the profound impacts of their delivery mode on immune response remain unrealized. Herein, immunostimulatory CpG-modified tumor-derived nanovesicles (CNVs) are used as a nanovaccine testbed to initially evaluate the impacts of three distinct delivery modes, including mono-pulse CNVs, staggered-pulse CNVs, and gel-confined CNVs. Fundamentally, delivery mode has enormous impacts on the immunomodulatory effects, altering the spatiotemporal distribution of nanovaccine residence and dendritic cell-T cell interaction in lymph nodes, and finally affecting subsequent T cell-mediated immune performance. As a result, the gel-confined delivery mode offers the best therapeutic performance in multiple tumor models. When extending evaluation to examine how the various delivery modes impact the performance of liposome-based nanovaccines, similar trends in intralymph node distribution and antitumor effect are observed. This work provides a strong empirical foundation that nanovaccine researchers should position delivery mode near the top of their considerations for the experimental design, which should speed up nanovaccine development and facilitate efficient selection of appropriate delivery modes in the clinic.

Citing Articles

Transformable Gel-to-Nanovaccine Enhances Cancer Immunotherapy via Metronomic-Like Immunomodulation and Collagen-Mediated Paracortex Delivery.

Jin S, Cho J, Gwak Y, Park S, Choi K, Choi J Adv Mater. 2024; 36(48):e2409914.

PMID: 39380383 PMC: 11602686. DOI: 10.1002/adma.202409914.


Advances in nano-immunotherapy for hematological malignancies.

Xu J, Liu W, Fan F, Zhang B, Sun C, Hu Y Exp Hematol Oncol. 2024; 13(1):57.

PMID: 38796455 PMC: 11128130. DOI: 10.1186/s40164-024-00525-3.


Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.

He A, Li X, Dai Z, Li Q, Zhang Y, Ding M J Nanobiotechnology. 2023; 21(1):236.

PMID: 37482608 PMC: 10364424. DOI: 10.1186/s12951-023-01989-x.


Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.

Xia Y, Fu S, Ma Q, Liu Y, Zhang N Nanomicro Lett. 2023; 15(1):145.

PMID: 37269391 PMC: 10239433. DOI: 10.1007/s40820-023-01125-2.


Synergy of Polydopamine Nanovaccine and Endostar Alginate Hydrogel for Improving Antitumor Immune Responses Against Colon Tumor.

Yang Y, Wang N, Tian X, Wang X, Yang J, Leng X Int J Nanomedicine. 2022; 17:4791-4805.

PMID: 36246936 PMC: 9554921. DOI: 10.2147/IJN.S372048.


References
1.
Reddy S, Swartz M, Hubbell J . Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006; 27(12):573-9. DOI: 10.1016/j.it.2006.10.005. View

2.
Moreira A, Rodrigues C, Jacinto T, Miguel S, Costa E, Correia I . Microneedle-based delivery devices for cancer therapy: A review. Pharmacol Res. 2019; 148:104438. DOI: 10.1016/j.phrs.2019.104438. View

3.
Hori Y, Stern P, Hynes R, Irvine D . Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials. 2009; 30(35):6757-67. PMC: 2788234. DOI: 10.1016/j.biomaterials.2009.08.037. View

4.
Bencherif S, Warren Sands R, Ali O, Li W, Lewin S, Braschler T . Injectable cryogel-based whole-cell cancer vaccines. Nat Commun. 2015; 6:7556. PMC: 4763944. DOI: 10.1038/ncomms8556. View

5.
Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S . T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545(7652):60-65. PMC: 5554367. DOI: 10.1038/nature22079. View